Promising combo may turn inoperable esophageal cancer into operable disease
Disease control
Recruiting now
This study tests whether adding the immunotherapy drug tislelizumab to standard chemoradiation can shrink advanced esophageal cancer enough to allow surgery. About 45 adults with unresectable esophageal squamous cell carcinoma will receive the combination, then possibly undergo s…
Phase: PHASE2 • Sponsor: Ming-Yu Lien • Aim: Disease control
Last updated May 13, 2026 16:01 UTC